CY1110168T1 - Παραγωγα των τρικυκλικων ν-ετεροαρυλο-καρβοξαμιδιων που περιεχουν ενα μοτιβο βενζιμιδαζολης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη - Google Patents

Παραγωγα των τρικυκλικων ν-ετεροαρυλο-καρβοξαμιδιων που περιεχουν ενα μοτιβο βενζιμιδαζολης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη

Info

Publication number
CY1110168T1
CY1110168T1 CY20101100609T CY101100609T CY1110168T1 CY 1110168 T1 CY1110168 T1 CY 1110168T1 CY 20101100609 T CY20101100609 T CY 20101100609T CY 101100609 T CY101100609 T CY 101100609T CY 1110168 T1 CY1110168 T1 CY 1110168T1
Authority
CY
Cyprus
Prior art keywords
denotes
benzimidazole
motif
tricyclic
heteroaryl
Prior art date
Application number
CY20101100609T
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Luc Even
Catherine Gille
André Malanda
David Machnik
Nathalie Rakotoarisoa
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1110168T1 publication Critical patent/CY1110168T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αφορά τα παράγωγα των τρικυκλικών N-ετεροαρυλο- καρβοξαμίδιων που περιέχουν ένα μοτίβο βενζιμιδαζόλης, γενικού τύπου (I) όπου το Α δηλώνει, με τον σύνδεσμο C-N του μοτίβου βενζιμιδαζόλης με το οποίο έχει τηχθεί, έναν μονοκυκλικό ετερόκυκλο ή έναν μονοκυκλικό ετερόκυκλο με 4 έως 7 κρίκους, που περιέχει από ένα έως τρία ετεροάτομα που επιλέγονται ανάμεσα από Ο, S ή Ν, συμπεριλαμβανομένου του ατόμου του αζώτου του μοτίβου βενζιμιδαζόλης. Το Ρ δηλώνει έναν δικυκλικό ετερόκυκλο ή δικυκλικό ετεροαρύλιο με 8-, 9-, 10 ή 11 κρίκους, που περιέχει από 1 έως 6 ετεροάτομα τα οποία επιλέγονται ανάμεσα από τα Ν, Ο και S. To Ri δηλώνει από ένα έως τέσσερα άτομα ή ομάδες, πανομοιότυπα ή διαφορετικά, το Υ δηλώνει ένα άτομο οξυγόνου ή θείου, το R2 δηλώνει ένα άτομο υδρογόνου, ένα άτομο αλογόνου, μια ομάδα C1C6-αλκυλίου, C3-C7- κυκλοαλκυλίου, C3C7-κυκλοαλκυλο-C1C3-αλκυλένιου, C1C6-φλουοροαλκυλίου ή C1C6-αλκοξέος, To R3 δηλώνει από ένα έως τρία άτομα ή ομάδες, πανομοιότυπα ή διαφορετικά, στην κατάσταση της βάσης ή του άλατος προσθήκης σε οξύ, καθώς και στην κατάσταση του ένυδρου στοιχείου ή του διαλύτη. Η εφεύρεση αφορά επίσης μια διαδικασία παρασκευής των ενώσεων και της εφαρμογής στη θεραπευτική.
CY20101100609T 2006-02-03 2010-07-01 Παραγωγα των τρικυκλικων ν-ετεροαρυλο-καρβοξαμιδιων που περιεχουν ενα μοτιβο βενζιμιδαζολης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη CY1110168T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0601007A FR2897061B1 (fr) 2006-02-03 2006-02-03 Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
EP07730900A EP1987010B1 (fr) 2006-02-03 2007-02-01 Dérivés de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
CY1110168T1 true CY1110168T1 (el) 2015-01-14

Family

ID=36954977

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100609T CY1110168T1 (el) 2006-02-03 2010-07-01 Παραγωγα των τρικυκλικων ν-ετεροαρυλο-καρβοξαμιδιων που περιεχουν ενα μοτιβο βενζιμιδαζολης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη

Country Status (33)

Country Link
US (2) US8143248B2 (el)
EP (1) EP1987010B1 (el)
JP (1) JP5136938B2 (el)
KR (1) KR20080090495A (el)
CN (1) CN101379041B (el)
AR (1) AR059279A1 (el)
AT (1) ATE463484T1 (el)
AU (1) AU2007211399B2 (el)
BR (1) BRPI0710480A2 (el)
CA (1) CA2637333C (el)
CY (1) CY1110168T1 (el)
DE (1) DE602007005779D1 (el)
DK (1) DK1987010T3 (el)
DO (1) DOP2007000022A (el)
EA (1) EA014450B1 (el)
ES (1) ES2344087T3 (el)
FR (1) FR2897061B1 (el)
HK (1) HK1129670A1 (el)
HR (1) HRP20100327T1 (el)
IL (1) IL192648A (el)
JO (1) JO2602B1 (el)
MA (1) MA30229B1 (el)
NO (1) NO20083520L (el)
NZ (1) NZ569669A (el)
PE (1) PE20071325A1 (el)
PL (1) PL1987010T3 (el)
PT (1) PT1987010E (el)
RS (1) RS51366B (el)
SI (1) SI1987010T1 (el)
TW (1) TWI401256B (el)
UY (1) UY30130A1 (el)
WO (1) WO2007088277A1 (el)
ZA (1) ZA200806139B (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
FR2911604B1 (fr) * 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
US20100113472A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
CN102388043A (zh) * 2009-02-11 2012-03-21 桑诺维恩药品公司 组胺h3反相激动剂和拮抗剂及其使用方法
JP2013504581A (ja) * 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンh3インバースアゴニストおよびアンタゴニストとその使用方法
WO2011136192A1 (ja) * 2010-04-27 2011-11-03 アステラス製薬株式会社 イミダゾ[1,2-a]ピリジン誘導体
WO2013138565A1 (en) * 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
MX354820B (es) * 2012-03-16 2018-03-21 Vitae Pharmaceuticals Inc Moduladores del receptor x del higado.
BR112014031731B1 (pt) 2012-06-18 2022-12-06 Dart Neuroscience (Cayman) Ltd Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10513694B2 (en) 2015-06-25 2019-12-24 Promega Corporation Thienopyrrole compounds and uses thereof
AU2017336074A1 (en) * 2016-09-30 2019-03-28 Epizyme, Inc. Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
EP3562823B1 (en) 2016-12-28 2023-02-08 Promega Corporation Functionalized nanoluc inhibitors
JP2020517618A (ja) 2017-04-21 2020-06-18 エピザイム,インコーポレイティド Ehmt2阻害剤との併用療法
CN109761974B (zh) * 2019-01-21 2021-05-14 河南大学 1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚类TRPV1拮抗剂及其应用
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブNuevolution A/S 核内受容体に対して活性の化合物
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
CN114276354B (zh) * 2022-01-07 2023-06-02 中山大学 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用
CN114539265B (zh) * 2022-03-02 2023-07-21 中山大学 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465207C (en) * 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
AU2003281044A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
US20040192728A1 (en) * 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
DE102004021716A1 (de) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
EP2314585B1 (en) * 2004-07-15 2012-09-12 Japan Tobacco, Inc. Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity

Also Published As

Publication number Publication date
PE20071325A1 (es) 2008-02-21
HRP20100327T1 (hr) 2010-08-31
CN101379041A (zh) 2009-03-04
EA200870226A1 (ru) 2009-02-27
JP5136938B2 (ja) 2013-02-06
SI1987010T1 (sl) 2010-07-30
RS51366B (en) 2011-02-28
NZ569669A (en) 2011-05-27
ZA200806139B (en) 2010-05-26
BRPI0710480A2 (pt) 2012-08-14
IL192648A0 (en) 2009-02-11
EA014450B1 (ru) 2010-12-30
CN101379041B (zh) 2012-08-29
EP1987010B1 (fr) 2010-04-07
UY30130A1 (es) 2007-09-28
US20090042873A1 (en) 2009-02-12
AR059279A1 (es) 2008-03-19
KR20080090495A (ko) 2008-10-08
JP2009525313A (ja) 2009-07-09
US8143248B2 (en) 2012-03-27
US20120122852A1 (en) 2012-05-17
IL192648A (en) 2012-06-28
FR2897061B1 (fr) 2010-09-03
FR2897061A1 (fr) 2007-08-10
US8288376B2 (en) 2012-10-16
TW200738726A (en) 2007-10-16
TWI401256B (zh) 2013-07-11
PT1987010E (pt) 2010-06-25
DK1987010T3 (da) 2010-08-02
CA2637333A1 (fr) 2007-08-09
DE602007005779D1 (de) 2010-05-20
WO2007088277A1 (fr) 2007-08-09
DOP2007000022A (es) 2007-09-15
HK1129670A1 (en) 2009-12-04
CA2637333C (fr) 2015-12-29
PL1987010T3 (pl) 2010-09-30
AU2007211399B2 (en) 2012-09-20
EP1987010A1 (fr) 2008-11-05
NO20083520L (no) 2008-09-11
MA30229B1 (fr) 2009-02-02
ATE463484T1 (de) 2010-04-15
JO2602B1 (en) 2011-11-01
AU2007211399A1 (en) 2007-08-09
ES2344087T3 (es) 2010-08-17

Similar Documents

Publication Publication Date Title
CY1110168T1 (el) Παραγωγα των τρικυκλικων ν-ετεροαρυλο-καρβοξαμιδιων που περιεχουν ενα μοτιβο βενζιμιδαζολης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
CY1122933T1 (el) Ενωσεις θειαζολοκαρβοξαμιδιων και πυριδινοκαρβοξαμιδιου χρησιμες ως αναστολεις κινασης ριμ
CY1121724T1 (el) Ενωσεις για την αντιμετωπιση καρκινου
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
EA201070873A1 (ru) Производные n-азабициклических карбоксамидов, их получение и применение в терапии
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
CY1115657T1 (el) Θεραπεια της μυϊκης δυστροφιας duchenne
CY1113470T1 (el) Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολο-2-καρβοξαμιδιων ως ανταγωνιστες υποδοχεων τυπου trpv1 ή vr1
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20090905A1 (es) Compuestos heterociclicos de amidas como inhibidores de la proteincinasa
CY1112997T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟ[1,5-α]ΠΥΡΙΔΙΝΩΝ, Η ΔΙΑΔΙΚΑΣIΑ ΠΑΡΑΣΚΕΥΗΣ ΤΟΥΣ ΚΑΙ ΟΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠΕΡΙΕΧΟΥΝ
PE20091268A1 (es) Derivados heterociclicos como inhibidores de pi3 quinasa
EA201270339A1 (ru) Замещенные производные ксантина
ECSP10010359A (es) Derivados bicíclicos de carboxamidas aza-bicíclicas, su preparación y su aplicación terapéutica
EA201171000A1 (ru) Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
CY1113649T1 (el) Θεραπευτικα μεσα
EA201070890A1 (ru) Замещенные ариламидные производные оксазепинопиримидона
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
NI201000039A (es) Derivados de quinazolinadiona, su preparación y sus aplicaciones terapéuticas.
CY1115239T1 (el) Αντιμικροβιακες ενωσεις
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
CY1115800T1 (el) Παραγωγα της 3-(ετεροαρυλο-αμινο)-1,2,3,4-τετραϋδρo-9η-καρβαζολης και η χρηση τους ως ρυθμιστες των υποδοχεων της προσταγλανδινης d2